Clinical Trial Management System Market

Clinical Trial Management System Market by Product (Software, Services), Delivery (Web-hosted, On-premise, Cloud-based), Deployment (Enterprise, On-site), End User (Pharma, Medical Device Manufacturers, CROs) - Global Forecasts to 2025

Report Code: HIT 1686 Jan, 2021, by marketsandmarkets.com

[150 Pages Report] The clinical trial management system market is projected to reach USD 1,590 million by 2025 from USD 801 million in 2020, at a CAGR of 14.7 % during the forecast period. The growth of the CTMS market is driven by rising industry-academia collaborations, the increasing number of clinical trials, rising technology adoption, and government support for research trials. However, budget constraints and limited knowledge about advanced CTMS solutions restrain the market growth

Clinical Trial Management System/CTMS Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the global Clinical Trial Management Market

Due to the COVID-19 outbreak, medical practices across all specialties and practices are under immense pressure; providers worldwide have been overwhelmed by the large and increasing number of patients. The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, CTMS has proven to be very helpful, as it allows industrial & academic researchers to monitor patients using digitally connected platforms while helping to organize & evaluate the clinical data for regulatory submissions.

The COVID-19 pandemic has also increased the need for social distancing among physicians and patients, which has driven the demand for remote patient monitoring and digital solutions for clinical research data gathering and analysis. Various players in this market have introduced COVID-19-associated features into their existing EHRs, which are being made available to users free of cost.

Clinical Trial Management System Market Dynamics

Driver: The rising number of clinical trials and the availability of advanced CTMS solutions

The life science industry is annually witnessing a global increase in the number of clinical trials. The growth in the number of clinical trials can be attributed to factors such as the high prevalence of chronic diseases, the expiry of blockbuster drugs, the availability of government funds for clinical trials, and fierce competition in the pharmaceutical industry. In recent years, leading players have launched many CTMS solutions in the market that boast superior performance than their traditional counterparts. These products are cost-effective, easy to use, provide effective patient safety and regulatory compliance, and enhance the financial management capabilities of users. They enable organizations to implement a full-featured CTMS without the complex configuration and heavy capital investment associated with traditional solutions.

Listed below are some significant products launched in recent years:

  • In December 2020, ERT launched a new product, Data Insights, to its Trial Oversight Solution to discover variabilities during collection and manage endpoint data.
  • In January 2020, Veeva launched Veeva Vault payment, an application for the Veeva Vault CTMS.
  • In January 2017, Bio-Optronics launched the latest version of its Clinical Conductor CTMS with enhanced patient management solutions and improved efficiency.
  • In November 2016, DATATRAK launched an innovative clinical trial management system, CTMS 360°. This is an SaaS platform that allows seamless access to data in real-time and provides current study status updates.

Restraint: Budget Constraints

Small and mid-sized customer facilities often face financial constraints for clinical trials due to limited private funding, rigorous regulatory mandates, and financial outlook. This also includes ineffective site selection, poor study design & trial execution, safety issues, and dropouts due to practical or financial issues. Furthermore, the time and capital required to complete a trial increase at each phase. The total cost of a Phase III failure includes the cost of all previous phases, plus the time that could have been used to trial a different drug. Each failed trial contributes to the rising costs of biopharma R&D. Although R&D spending in the life science industry is rising, start-ups and SMEs still face budget constraints, which affect their decision to purchase CTMS solutions. Due to uncertainties in product approvals, undue delays in product approvals, and long gestation periods, private investors usually prefer established firms to invest in rather than start-ups and SMEs.

Opportunity: Investment in effective digital infrastructure and agility in technological adoption

The need to comply with stringent regulations has been crucial to expediting the adoption of new technology in research. Although the supply of technology has been increasing and the regulation of innovative methods is easing, pharmaceutical companies have been slow to use emerging technologies due to the uncertainty prevailing around this space and a highly fragmented supply market. Lately, pharma companies have increased expenditure on AI and big data analytics, given their transformative supremacy over the R&D process and cost savings. Fear of rivalry in the market and the need for business transformation and agility are key forces driving huge investments in R&D technologies. Hence, pharma companies must recognize outward innovation through supplier benchmarking in each of these categories and be involved in early engagement through co-development to stay competitive.

Challenge: Lack of skilled professionals

The dearth of skilled professionals for handling sophisticated digital solutions in research teams is restraining the growth of the CTMS market. With severe time constraints and increasing cost cuts, CROs and pharmaceutical companies are reluctant to invest in training their research employees. Hence, a huge gap exists between the available and required skilled manpower in the clinical research industry, restricting the adoption and utilization of complex software solutions in clinical trials. The development of user-friendly software solutions could act as a key growth opportunity for software vendors in this market.

By deployment mode, enterprise-wide segment to register significant growth during the forecast period.

Based on the deployment mode, the clinical trial management system market is segmented into enterprise-wide and on-site CTMS. The enterprise-wide segment accounted for the largest share in the year 2019. The large share of this segment can be attributed to its widespread adoption by the majority of end users due to its benefits

IBy delivery mode, web-based (on demand) segment to register significant growth during the forecast period.

Based on the delivery mode, the clinical trial management system market is segmented into web-based (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) clinical trial management system. Among these, the web-based segment dominated the market in 2019.  The large share of this segment can be attributed to the advantages offered by web-based software, such as easy access, improved productivity, and time and cost-efficiency.

By products & service, software segment to register significant growth during the forecast period.

Based on product & service, the clinical trial management system market is segmented into software and services. Rising R&D expenditure, an increasing number of clinical trials, and the growing adoption of clinical trial management solutions are some of the key factors driving the growth of the software market.

Large pharma-biotech companies segment is expected to account for the largest share of the clinical trial management system market, by the end user

Based on end users, the clinical trial management system market has been segmented based on end-user category-large pharma-biotech companies, small & mid-sized pharma-biotech companies, CROs, medical device manufacturers, and other end users. One of the key factors driving the use of CTMS is an increasing emphasis on R&D. For instance, PhRMA member companies in the US increased their R&D expenditure from ~USD 26.0 billion in 2000 to USD 58.8 billion in 2015 (Source: Pharmaceutical Research and Manufacturers of America). Due to rising pressure of R&D costs, outcomes-based reimbursement, and stricter regulations imposed on large pharma companies, a part of their R&D functions is outsourced to smaller pharmaceutical companies, which increases the growth of companies in this category.

Clinical Trial Management System/CTMS Market   by Region

Asia Pacific market is expected to grow at the highest CAGR during the forecast period.

The Asia Pacific market is projected to register the highest CAGR during the forecast period. In 2019, Asia Pacific region is expected to offer significant opportunities for the growth of the clinical trial management system market. The major factors driving the growth of the Asia Pacific market include increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, faster rate of patient recruitment for clinical trials than mature nations, low operating costs for conducting clinical trials, a shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region.

Key Market Players

Oracle Corporation (US), Medidata Solutions (US), Parexel International (US), Bioclinica (US), and IBM (US), Bio-Optronics (US), Datatrak (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Advarra Technology Solutions (US), MedNet Solutions (US), ArisGlobal (US), DZS Clinical Services (US), Crucial Data Solutions (US), Ennov (France), DataStat (US), and RealTime Software Solutions LLC (US) among others are some of the major players operating in the global clinical trial management system market, among others.

As of 2019, Oracle Corporation (US) holds the leading position in the global CTMS market. It has a wide range of CTMS solutions and a broad customer base in over 145 countries. It primarily focuses on capability expansion and partnerships & collaborations to sustain its leading position in the CTMS market. In the past three years, the company partnered or collaborated with several industry stakeholders for collaborative research that utilizes CTMS solutions, such as FHI Clinical (US). Besides product launches, the company also acquired goBalto (aimed to strengthen its services & customer assistance capabilities across its customer base) and established the Oracle Cloud EU Center (Germany) to expand its market presence in Europe.

Scope of the report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD Million)

Segments covered

Deployment, Delivery, Product & Service, End User and Region

Geographies covered

Europe, North America, the Asia Pacific, Latin America, and Middle East and Africa

Companies covered

Oracle Corporation (US), Medidata Solutions (US), Parexel International (US), Bioclinica (US), IBM (US) Bio-Optronics (US), Datatrak (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Advarra Technology Solutions (US), MedNet Solutions (US), ArisGlobal (US), DZS Clinical Services (US), Crucial Data Solutions (US), Ennov (France), DataStat (US), and RealTime Software Solutions LLC (US).

This report has segmented the clinical trial management system market based on deployment, delivery, product & services, end user and region.

Global Clinical Trial Management System Market, by Deployment

  • Enterprise-wide CTMS
  • On-Site CTMS

Global Clinical Trial Management System Market, by Delivery

  • Web-based (On-demand)
  • Licensed Enterprise (On-premises)
  • Cloud-based (SaaS)

Global Clinical Trial Management System Market, by Product & Service

  • Software
  • Services

Global Clinical Trial Management System Market, by End User

  • Large Pharma-biotech Companies
  • CROs
  • Medical Device Manufacturers
  • Small & Mid-sized Pharma-biotech Companies
  • Other End Users

Global Clinical Trial Management System Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLA
  • Middle East & Africa

Recent Developments

In June 2019, Parexel International Corporation (US) launched an enhanced integrated outsourcing delivery model for functional service provider (FSP) services at the DIA 2019 Global Annual Meeting in San Diego, US.
In May 2019, Bio-optronics (US) launched three products to the CCTrialSuite basket application—CCeSource, CCeReg & CCeConsent.
In June 2018, Bioclinica (US) launched eClinical Solution namely the SMART Technology Suite.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 19)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY USED FOR THE STUDY
    1.5 MAJOR MARKET STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 23)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
           FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 END USER-BASED MARKET ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
           FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 31)
           FIGURE 6 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY PRODUCT AND SERVICE, 2020 VS. 2025 (USD MILLION)
           FIGURE 7 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT MODE, 2020 VS. 2025 (USD MILLION)
           FIGURE 8 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DELIVERY MODE, 2020 VS. 2025 (USD MILLION)
           FIGURE 9 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
           FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET

4 PREMIUM INSIGHTS (Page No. - 35)
    4.1 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET OVERVIEW
           FIGURE 11 INCREASING RESEARCH PARTNERSHIPS AND OUTSOURCING ARE DRIVING GROWTH IN THE CTMS MARKET
    4.2 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT MODE
           FIGURE 12 ENTERPRISE-WIDE DEPLOYMENT DOMINATES THE MARKET
    4.3 ASIA PACIFIC CLINICAL TRIAL MANAGEMENT SYSTEM MARKET
           FIGURE 13 LARGE PHARMA-BIOTECH COMPANIES FORM THE LARGEST END-USER SEGMENT IN THE ASIA PACIFIC MARKET
    4.4 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY REGION
           FIGURE 14 APAC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2020–2025)

5 MARKET OVERVIEW (Page No. - 38)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 15 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Significant operational costs and regulatory requirements associated with clinical research
                    5.2.1.2 Research partnerships between pharma-biopharma companies and CROs
                    5.2.1.3 The rising number of clinical trials and the availability of advanced CTMS solutions
                    5.2.1.4 Expansion of the target customer base
                    5.2.1.5 Rising government funding and grants to support clinical trials
           5.2.2 RESTRAINTS
                    5.2.2.1 Budget constraints
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing outsourcing of research processes
                    5.2.3.2 Greater integration with Platform-as-a-service (PaaS) and mobile computing
                    5.2.3.3 Investment in effective digital infrastructure and agility in technological adoption
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
                    5.2.4.2 Fragmented and highly regulated industry
                    5.2.4.3 Patient privacy
                    5.2.4.4 Limited awareness among researchers about associated advantages
           5.2.5 KEY TRENDS
                    5.2.5.1 Integration of CTMS with software such as HIS, EMR, and EDC
                    5.2.5.2 Mergers and acquisitions
                    5.2.5.3 Shift from manual data interpretation to real-time data analysis during clinical studies
    5.3 IMPACT OF COVID-19 ON THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET
    5.4 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS)
           5.4.1 ECOSYSTEM COVERAGE: CTMS MARKET
    5.5 MAJOR USE CASES: PARENT MARKET (LIFE SCIENCE ANALYTICS SOLUTIONS)

6 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT TYPE (Page No. - 47)
    6.1 INTRODUCTION
           TABLE 1 CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
    6.2 ENTERPRISE-WIDE CTMS
           6.2.1 ENTERPRISE-WIDE CTMS IS PREFERRED BY END USERS
           TABLE 2 ENTERPRISE-WIDE CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.3 ON-SITE CTMS
           6.3.1 ON-SITE CTMS SUPPORTS IMPROVED CLINICAL TRAILS
           TABLE 3 ON-SITE CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)

7 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DELIVERY MODE (Page No. - 50)
    7.1 INTRODUCTION
           TABLE 4 CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
    7.2 WEB-BASED (ON-DEMAND) CTMS
           7.2.1 PROVISION OF CENTRALIZED MANAGEMENT IN CLINICAL TRIALS TO AID THE ADOPTION OF WEB-BASED CTMS
           TABLE 5 WEB-BASED (ON-DEMAND) CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.3 LICENSED ENTERPRISE (ON-PREMISES) CTMS
           7.3.1 MINIMIZED RISK OF DATA BREACHES AND EXTERNAL ATTACKS SUPPORTS THE USE OF ON-PREMISES CTMS MODELS
           TABLE 6 LICENSED ENTERPRISE (ON-PREMISES) CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.4 CLOUD-BASED (SAAS)
           7.4.1 HIGH ADAPTABILITY AND RELIABILITY TO AID ADOPTION OF CLOUD-BASED SOLUTIONS
           TABLE 7 CLOUD-BASED (SAAS) CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)

8 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY PRODUCT & SERVICE (Page No. - 55)
    8.1 INTRODUCTION
           TABLE 8 CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
    8.2 SOFTWARE
           8.2.1 RISING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
           TABLE 9 CTMS MARKET FOR SOFTWARE, BY REGION, 2018–2025 (USD MILLION)
    8.3 SERVICES
           8.3.1 NEED FOR CONTINUOUS UPGRADATION OF CTMS SOFTWARE HAS INCREASED THE DEMAND FOR SERVICES
           TABLE 10 CTMS MARKET FOR SERVICES, BY REGION, 2018–2025 (USD MILLION)

9 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY END USER (Page No. - 58)
    9.1 INTRODUCTION
           TABLE 11 CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.2 LARGE PHARMA-BIOTECH COMPANIES
           9.2.1 LARGE PHARMA-BIOTECH COMPANIES DOMINATE THE END-USER MARKET
           FIGURE 16 ACTIVE PHARMACEUTICAL PIPELINE, 2009–2019
           TABLE 12 CTMS MARKET FOR LARGE PHARMA-BIOTECH COMPANIES, BY REGION, 2018–2025 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS
           9.3.1 RISING OUTSOURCING AND GROWING CRO PRESENCE ARE KEY GROWTH DRIVERS
           TABLE 13 CTMS MARKET FOR CROS, BY REGION, 2018–2025 (USD MILLION)
    9.4 MEDICAL DEVICE MANUFACTURERS
           9.4.1 NEED TO COMPLY WITH REGULATIONS AND ENSURE PRODUCT SAFETY AND QUALITY HAVE SUPPORTED USE OF CTMS
           FIGURE 17 R&D SPENDING OF LEADING MEDICAL DEVICE COMPANIES (2018)
           TABLE 14 CTMS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION,2018–2025 (USD MILLION)
    9.5 SMALL & MID-SIZED PHARMA-BIOTECH COMPANIES
           9.5.1 RISE IN OUTSOURCING TO SMALLER PHARMA COMPANIES IS A KEY DRIVER OF MARKET GROWTH
           TABLE 15 CTMS MARKET FOR SMALL & MID-SIZED PHARMA-BIOTECH COMPANIES,BY REGION, 2018–2025 (USD MILLION)
    9.6 OTHER END USERS
           TABLE 16 CTMS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)

10 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY REGION (Page No. - 65)
     10.1 INTRODUCTION
           TABLE 17 CTMS MARKET, BY REGION, 2018–2025 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 18 NORTH AMERICA: CTMS MARKET SNAPSHOT
           TABLE 18 NORTH AMERICA: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 19 NORTH AMERICA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 20 NORTH AMERICA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 21 NORTH AMERICA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 22 NORTH AMERICA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.2.1 US

           TABLE 23 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
           TABLE 24 US: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 25 US: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 26 US: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 27 US: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
           TABLE 28 CANADA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 29 CANADA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 30 CANADA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 31 CANADA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.3 EUROPE
           TABLE 32 EUROPE: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 33 EUROPE: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 34 EUROPE: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 35 EUROPE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 36 EUROPE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 High investments and initiatives in Germany to boost market growth
           TABLE 37 GERMANY: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 38 GERMANY: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 39 GERMANY: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 40 GERMANY: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Favorable R&D scenario in the country to boost software adoption
           TABLE 41 UK: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 42 UK: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 43 UK: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 44 UK: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 High number of oncology clinical trials in France to drive market growth
           TABLE 45 FRANCE: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 46 FRANCE: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 47 FRANCE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 48 FRANCE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Low drug approval times have driven the adoption of CTMS, supporting market growth
           TABLE 49 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
           TABLE 50 ITALY: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 51 ITALY: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 52 ITALY: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 53 ITALY: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Rising R&D expenditure to propel the growth of the Spanish market
           TABLE 54 SPAIN: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 55 SPAIN: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 56 SPAIN: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 57 SPAIN: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.6 REST OF EUROPE
           TABLE 58 ROE: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 59 ROE: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 60 ROE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 61 ROE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.4 ASIA PACIFIC
           FIGURE 19 APAC: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET SNAPSHOT
           TABLE 62 ASIA PACIFIC: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 63 ASIA PACIFIC: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 64 ASIA PACIFIC: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 65 ASIA PACIFIC: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 66 ASIA PACIFIC: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth
           TABLE 67 CHINA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 68 CHINA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 69 CHINA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 70 CHINA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Stringent regulatory scenario in Japan to restrain the market growth
           TABLE 71 JAPAN: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 72 JAPAN: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 73 JAPAN: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 74 JAPAN: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Favorable pharmaceutical R&D scenario to drive software adoption
           TABLE 75 INDIA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 76 INDIA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 77 INDIA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 78 INDIA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 Government support for clinical trials to boost the market in Australia
           TABLE 79 AUSTRALIA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 80 AUSTRALIA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 81 AUSTRALIA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 82 AUSTRALIA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Growth of the contract research sector indicates opportunities for CTMS providers
           TABLE 83 SOUTH KOREA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 84 SOUTH KOREA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 85 SOUTH KOREA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 86 SOUTH KOREA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
           TABLE 87 ROAPAC: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 88 ROAPAC: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 89 ROAPAC: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 90 ROAPAC: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 RISING INVESTMENTS AND HEALTHCARE EXPENDITURE SHOW POTENTIAL FOR MARKET GROWTH
           TABLE 91 LATAM: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 92 LATAM: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 93 LATAM: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 94 LATAM: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA
             10.6.1 GROWING AVAILABILITY OF FUNDING IN THE MIDDLE EAST INDICATES OPPORTUNITIES FOR MARKET GROWTH
           TABLE 95 MEA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 96 MEA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION)
           TABLE 97 MEA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION)
           TABLE 98 MEA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 103)
     11.1 OVERVIEW
           FIGURE 20 KEY DEVELOPMENTS IN THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET (2017–2020)
     11.2 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEM MARKET SHARE ANALYSIS (2019)
           FIGURE 21 ORACLE HELD THE LEADING POSITION IN THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET IN 2019
     11.3 COMPETITIVE SCENARIO (2017–2020)
             11.3.1 KEY PRODUCT LAUNCHES AND PRODUCT DEPLOYMENTS (2017–2020)
             11.3.2 KEY EXPANSIONS (2017–2020)
             11.3.3 KEY MERGERS, DIVESTITURES, AND ACQUISITIONS (2017–2020)
             11.3.4 KEY AGREEMENTS, CONTRACTS, AND PARTNERSHIPS (2017–2020)
     11.4 COMPETITIVE LEADERSHIP MAPPING
     11.5 VENDOR INCLUSION CRITERIA
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
           FIGURE 22 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019
     11.6 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2019)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
           FIGURE 23 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019 (SMES/START-UPS)

12 COMPANY PROFILES (Page No. - 111)
     12.1 ORACLE
           FIGURE 24 ORACLE: COMPANY SNAPSHOT
     12.2 MEDIDATA SOLUTIONS
           FIGURE 25 MEDIDATA SOLUTIONS: COMPANY SNAPSHOT
     12.3 PAREXEL INTERNATIONAL CORPORATION
     12.4 IBM
           FIGURE 26 IBM: COMPANY SNAPSHOT
     12.5 BIOCLINICA
     12.6 BIO-OPTRONICS
     12.7 DATATRAK INTERNATIONAL
           FIGURE 27 DATATRAK INTERNATIONAL: COMPANY SNAPSHOT
     12.8 VEEVA SYSTEMS
           FIGURE 28 VEEVA SYSTEMS: COMPANY SNAPSHOT
     12.9 MASTERCONTROL
     12.10 DSG
     12.11 ERT
     12.12 ADVARRA TECHNOLOGY SOLUTIONS
     12.13 MEDNET SOLUTIONS
     12.14 ARISGLOBAL
     12.15 DZS CLINICAL SERVICES (WDB HOLDINGS CO. LTD)
     12.16 EMERGING PLAYERS/START-UPS
             12.16.1 CRUCIAL DATA SOLUTIONS (CDS)
             12.16.2 ENNOV
             12.16.3 DATASTAT
             12.16.4 BSI
             12.16.5 REALTIME SOFTWARE SOLUTIONS LLC

13 APPENDIX (Page No. - 141)
     13.1 RESEARCH DATA
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical trial management system market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Primary research was conducted after acquiring extensive knowledge about the global clinical trial management system market scenario through secondary research. Primary interviews were conducted with market experts from both the demand-side (such as hospitals, ambulatory surgery centers, outpatient facilities, clinics, research universities, academic institutions, and government institutions, among others) and supply-side respondents (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers) across five major geographies, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa. Approximately 30% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 70%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below

Clinical Trial Management System/CTMS Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

A detailed market estimation approach was followed to estimate and validate the size of the global clinical trial management system market and other dependent submarkets.

  • The key players in the global clinical trial management system market were identified through secondary research, and their global market shares were determined through primary and secondary research.
  • The research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights on the global clinical trial management system market.
  • All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.
  •  All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Clinical Trial Management System/CTMS Market  Size, Estimation

Data Triangulation:

After deriving the overall clinical trial management system market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macroindicators.

Report Objectives:

  • To define, describe, and forecast the clinical trial management system market based on product & service, deployment mode, deployment type, and end user
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall clinical trial management system market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To estimate the size & growth potential of the market segments and subsegments with respect to five key regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa—and key countries
  • To profile the key players in the market and comprehensively analyze their global revenue shares and core competencies
  • To track and analyze competitive developments, such as product launches and approvals, partnerships, agreements, collaborations, and acquisitions in the market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the global clinical trial management system market report:

Product analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

CROs Market Segmentation, by Clinical Trial Phase

  • Further segmentation of the CROs market, by clinical trial phase (phases I to IV)

Company information

  • Detailed analysis and profiling of additional market players (up to five)

Geographic analysis

  • Further breakdown of the Rest of Europe CTMS market into Belgium, Austria, Denmark, Greece, Poland, and Russia, among other countries
  • Further breakdown of the Rest of Asia Pacific CTMS market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  • Further breakdown of the Rest of Latin America CTMS market into Argentina and Colombia, among other countries
COVID-19

Get in-depth analysis of the COVID-19 impact on the Clinical Trial Management System Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Clinical Trial Management System Market

Request For Special Pricing
Report Code
HIT 1686
Published ON
Jan, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Clinical Trial Management System Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved